Canada - English - Health Canada

mylan pharmaceuticals ulc - selegiline hydrochloride - tablet - 5mg - selegiline hydrochloride 5mg - monoamine oxidase b inhibitors

Canada - English - Health Canada

aa pharma inc - selegiline hydrochloride - tablet - 5mg - selegiline hydrochloride 5mg - monoamine oxidase b inhibitors

Ireland - English - HPRA (Health Products Regulatory Authority)

ceva animal health limited - selegiline hydrochloride - film-coated tablet - 16.74 mg/tablet - antidepressants - dogs - neurological preparations

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - selegiline hydrochloride -

Ireland - English - HPRA (Health Products Regulatory Authority)

ceva santé animale - selegiline hydrochloride - film-coated tablet - 16.74 mg/tablet - antidepressants

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - selegiline hydrochloride, quantity: 5 mg - tablet, uncoated - excipient ingredients: citric acid monohydrate; purified talc; maize starch; magnesium stearate; povidone; lactose monohydrate - may be of benefit as an adjunct in the management of late stage parkinson's disease in patients being treated with levodopa with/without a peripheral decarboxylase inhibitor, who exhibit deterioration in the quality of their response of therapy. indications as at 1 december 1999: treatment of patients with parkinson's disease. it can be used as monotherapy in the early phases of the disease and as adjunctive therapy with levodopa (with/without a peripheral decarboxylase inhibitor).

United States - English - NLM (National Library of Medicine)

zoetis inc. - selegiline hydrochloride (unii: 6w731x367q) (selegiline - unii:2k1v7gp655) - selegiline hydrochloride 2 mg - anipryl tablets are indicated for the control of clinical signs associated with canine cognitive dysfunction syndrome (cds) and control of clinical signs associated with uncomplicated canine pituitary dependent hyperadrenocorticism (pdh). anipryl is contraindicated in patients with known hypersensitivity to this drug.  in humans, selegiline is contraindicated for use with meperidine and this contraindication is often extended to other opioids.

United States - English - NLM (National Library of Medicine)

a-s medication solutions - selegiline hydrochloride (unii: 6w731x367q) (selegiline - unii:2k1v7gp655) - selegiline hydrochloride tablets usp are indicated as an adjunct in the management of parkinsonian patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. there is no evidence from controlled studies that selegiline has any beneficial effect in the absence of concurrent levodopa therapy. evidence supporting this claim was obtained in randomized controlled clinical investigations that compared the effects of added selegiline or placebo in patients receiving levodopa/carbidopa. selegiline was significantly superior to placebo on all three principal outcome measures employed: change from baseline in daily levodopa/carbidopa dose, the amount of 'off' time, and patient self-rating of treatment success. beneficial effects were also observed on other measures of treatment success (e.g., measures of reduced end of dose akinesia, decreased tremor and sialorrhea, improved speech and dressing ability and improved overall disability as assessed by walking

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - selegiline hydrochloride 5mg;  ;  ;   - tablet - 5 mg - active: selegiline hydrochloride 5mg       excipient: lactose monohydrate magnesium stearate microcrystalline cellulose starch

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - selegiline hydrochloride - oral tablet - 5mg